Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management

View through CrossRef
DA-1726 is being prepared for obesity Phase 1 clinical trials following IND approval. Our study focuses on the pharmacological effects of this novel oxyntomodulin analogue, which has been effective at improving lipid profiles and reducing weight in rodent models. In a prior study, DA-1726 showed a difference in improving lipid levels, despite similar weight loss to tirzepatide. Therefore, the direct lipid-regulating effect of DA-1726 was assessed in a hypercholesterolemia rat model compared with tirzepatide. As a result, DA-1726 was more effective than tirzepatide in suppressing the elevation of T-CHO ( -33.5%, -25.5% vs. control; P<0.05) and LDL-C (-53.2%, -41.5% vs. control; P<0.05). This differentiated impact is thought to arise from DA-1726's glucagon action, alongside its GLP-1 effect. We evaluated whether these differential effects could also be distinguished from drugs of the same class. In an obese mouse model, DA-1726 significantly lowered T-CHO (-67.7%, -49.6%; P<0.05 vs. control) and TG (-49.5%, -41.2%; P<0.05 vs. control) levels under conditions that resulted in similar weight loss effects (-31.9%, -25.4%; P<0.05 vs. control) as survodutide. Besides, DA-1726 exhibited superior glucose lowering compared to survodutide (-54.7%, -30.4% vs. control; P<0.05). Interestingly, despite the same mechanism of action, DA-1726-treated mice maintained similar levels of weight loss while consuming more food due to less dietary restriction in terms of appetite suppression. This effect might stem from DA-1726's GLP-1 and glucagon receptor activity ratio. DA-1726's glucagon action could further enhance energy expenditure (EE), and it is believed to have significantly increased the expression of EE-related genes in brown adipose tissue. In summary, it was confirmed that DA-1726 has differentiating characteristics in the competition of obesity treatment drugs with similar or identical mechanisms in its effect on improving cholesterol metabolism through glucagon action. Disclosure Y. Chae: None. I. Jung: None. T. Kim: None. M. Kim: None. S. Lee: None. H. Kim: Employee; NeuroBo Pharamceuticals Inc., Dong-A ST Co., Ltd.
Title: 2058-LB: DA-1726, a GLP1R/GCGR Dual Agonist, a Promising Approach in Obesity Treatment and Lipid Management
Description:
DA-1726 is being prepared for obesity Phase 1 clinical trials following IND approval.
Our study focuses on the pharmacological effects of this novel oxyntomodulin analogue, which has been effective at improving lipid profiles and reducing weight in rodent models.
In a prior study, DA-1726 showed a difference in improving lipid levels, despite similar weight loss to tirzepatide.
Therefore, the direct lipid-regulating effect of DA-1726 was assessed in a hypercholesterolemia rat model compared with tirzepatide.
As a result, DA-1726 was more effective than tirzepatide in suppressing the elevation of T-CHO ( -33.
5%, -25.
5% vs.
control; P<0.
05) and LDL-C (-53.
2%, -41.
5% vs.
control; P<0.
05).
This differentiated impact is thought to arise from DA-1726's glucagon action, alongside its GLP-1 effect.
We evaluated whether these differential effects could also be distinguished from drugs of the same class.
In an obese mouse model, DA-1726 significantly lowered T-CHO (-67.
7%, -49.
6%; P<0.
05 vs.
control) and TG (-49.
5%, -41.
2%; P<0.
05 vs.
control) levels under conditions that resulted in similar weight loss effects (-31.
9%, -25.
4%; P<0.
05 vs.
control) as survodutide.
Besides, DA-1726 exhibited superior glucose lowering compared to survodutide (-54.
7%, -30.
4% vs.
control; P<0.
05).
Interestingly, despite the same mechanism of action, DA-1726-treated mice maintained similar levels of weight loss while consuming more food due to less dietary restriction in terms of appetite suppression.
This effect might stem from DA-1726's GLP-1 and glucagon receptor activity ratio.
DA-1726's glucagon action could further enhance energy expenditure (EE), and it is believed to have significantly increased the expression of EE-related genes in brown adipose tissue.
In summary, it was confirmed that DA-1726 has differentiating characteristics in the competition of obesity treatment drugs with similar or identical mechanisms in its effect on improving cholesterol metabolism through glucagon action.
Disclosure Y.
Chae: None.
I.
Jung: None.
T.
Kim: None.
M.
Kim: None.
S.
Lee: None.
H.
Kim: Employee; NeuroBo Pharamceuticals Inc.
, Dong-A ST Co.
, Ltd.

Related Results

1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
1668-P: Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
DA-1726 is a novel oxyntomodulin analogue preparing for phase I clinical trials for obesity. In this study, the pharmacological effect of DA-1726 compared to other competitor pepti...
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
1908-P: Glucagon Receptor Expression Evaluated by Antibody-Dependent and -Independent Approaches
Glucagon regulates metabolic functions through the glucagon receptor (GCGR). Agonists as well as antagonists of GCGR are evaluated as treatments of diabetes and obesity. To underst...
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
ABHD17A-driven GLP1R depalmitoylation rewired G-protein coupling to impair periodontal ligament stem cell homeostasis in periodontitis
Periodontitis is characterized by persistent inflammation and impaired periodontal regeneration, but the mechanism linking these processes remains unclear. Here, we identified a pa...
1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
1676-P: A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
DA-1726 showed superior weight loss efficacy compared to Semaglutide (SEMA) in DIO mice. In this following study, a dose-response of DA-1726 was evaluated to determine the maximum ...
Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
Antitumor Activity of An RNA-Based Agonist of TLR7 and 8 In Preclinical Models of Hematological Malignancies
Abstract Abstract 421 Treatment of hematological malignancies, non-Hodgkins lymphoma in particular, has evolved greatly in the past decade with the ad...
1894-P: Interruption of Glucagon Signaling Increases Pancreas Mass
1894-P: Interruption of Glucagon Signaling Increases Pancreas Mass
Interruption of glucagon signaling by glucagon receptor gene inactivation or treatment with a glucagon receptor blocking monoclonal antibody (GCGR-Ab) stimulates alpha cell prolife...
Obstacles and Impediments of Overweight and Obesity
Obstacles and Impediments of Overweight and Obesity
Obesity is now pandemic, affecting millions of people in worldwide [1]. Obesity is defined as the excessive fat accumulation which may damage the health. Two groups of beneficial b...

Back to Top